KPRX on Nasdaq

KIORA PHARMACEUTICALS INC

American pharmaceutical preparations company based in Encinitas.

Price unavailable

Last updated Oct 18, 2026.

Overview

Compare with uniQure N.V., Zhengye Biotechnology Holding Ltd or VERU INC., or pick any stock.

  • TickerKPRX on Nasdaq
  • IndustryPharmaceutical Preparations
  • HeadquartersWaltham, United States
  • Incorporated inDE2
  • Business address169 Saxony Rd., Suite 212, Encinitas, Ca 920242
  • Filer categoryNon-accelerated filer, Smaller reporting company2

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-100.0%Revenue growth, 20253
-67.2%Return on equity3
-$10.1MFree cash flow3

Financial statements

Revenue4563$0 in 2025
0$5.0M$10.0M$15.0M$20.0M2019: $2.7M$2.7M20192020: $12.1K$12.1K2020−100%2021: $0$020212023: $0$020232024: $16.0M$16.0M20242025: $0$02025
Operating income57863-$12.8M in 2025+87% since 2020
-$15.0M-$10.0M-$5.0M0$5.0M2020: -$6.9M-$6.9M20202021: -$14.2M-$14.2M2021+107%2022: -$12.3M-$12.3M2022−14%2023: -$12.6M-$12.6M2023+2%2024: $4.5M$4.5M20242025: -$12.8M-$12.8M2025
Net income457863-$10.8M in 2025+53% since 2019
-$15.0M-$10.0M-$5.0M0$5.0M2019: -$7.1M-$7.1M20192020: -$6.9M-$6.9M2020−3%2021: -$13.8M-$13.8M2021+101%2022: -$13.6M-$13.6M2022−1%2023: -$12.5M-$12.5M2023−8%2024: $3.6M$3.6M20242025: -$10.8M-$10.8M2025

Every line of the income statement as filed: the last 2 fiscal years, latest first.3

Period ending2025-12-312024-12-31
Collaboration Revenue$0$16.0M
Grant Revenue$0$20.0K
Total Revenue$0$16.0M
General and Administrative$5.7M$5.5M
Research and Development$10.8M$7.8M
Collaboration Credits-$7.1M-$2.9M
In-Process R&D Impairment$4.6M$2.0M
Change in Fair Value of Contingent Consideration-$1.3M-$937.5K
Total Operating Expenses$12.8M$11.5M
Operating (Loss) Income Before Other Income (Expense), Net-$12.8M$4.5M
Impairment of Intangible Assets$0-$104.2K
Loss on Disposal of Fixed Assets$0-$3.9K
Interest Income$894.0K$1.3M
Interest Expense-$20.0K-$21.4K
Other (Expense) Income, Net-$160.3K$26.1K
Total Other Income, Net$713.8K$1.1M
(Loss) Income Before Income Tax Expense-$12.1M$5.7M
Income Tax Benefit (Expense)$1.3M-$2.1M
Net (Loss) Income Attributable to Common Shareholders, basic-$10.8M$3.6M
Net (Loss) Income Attributable to Common Shareholders, diluted-$10.8M$3.6M
Net (Loss) Income per Common Share - Basic (in usd per share)-$2.60$0.93
Weighted Average Shares Outstanding - Basic (in shares)4.2M shares3.9M shares
Net (Loss) Income per Common Share - Diluted (in usd per share)-$2.64$0.87
Weighted Average Shares Outstanding - Diluted (in shares)4.1M shares4.1M shares
Net (Loss) Income-$10.8M$3.6M
Unrealized (Loss) Gain on Marketable Securities-$20.1K$29.7K
Foreign Currency Translation Adjustments$56.1K-$129.1K
Comprehensive (Loss) Income-$10.8M$3.5M

Compare KIORA PHARMACEUTICALS INC with another company

Leadership

Who has led KIORA PHARMACEUTICALS INC, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Stephen From2015–2021
  2. Franz Obermayr2021
  3. Brian M. Strem2021–now

Chair

  1. Stephen From2021–2022

President

  1. Stephen From2015–2021
  2. Brian M. Strem2021–now

Chief financial officer

  1. Ryan Randall Brenneman2016
  2. Sarah Romano2017–2022
  3. Susan L. Drexler2022
  4. Melissa Tosca2024–now
20202025
Board members and other officers (21)

Former names

  • EYEGATE PHARMACEUTICALS INCAug 9, 2006 to Nov 4, 20212

Timeline

  1. Aug 2, 2021New chief executive Brian M. Strem becomes CEO12
  2. Feb 3, 2021New chief executive Franz Obermayr becomes CEO11
  3. Feb 12, 2015New chief executive Stephen From becomes CEO13
  4. Dec 28, 2004Founded KIORA PHARMACEUTICALS INC is founded38

Filings

304 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 71 major events, 96 insider forms, 40 large holders, 5 private raises, 71 other. The latest 20:

  1. Sep 17, 2026SCHEDULE 13G EDGAR
  2. Sep 17, 20264 EDGAR
  3. Sep 17, 20263 EDGAR
  4. Sep 8, 20268-K EDGAR
  5. Aug 19, 20268-K EDGAR
  6. Aug 14, 2026SCHEDULE 13G/A EDGAR
  7. Aug 14, 2026SCHEDULE 13G/A EDGAR
  8. Aug 10, 2026SCHEDULE 13G EDGAR
  9. Aug 7, 20268-K EDGAR
  10. Aug 7, 202610-Q EDGAR
  11. Jul 2, 20264 EDGAR
  12. Jul 2, 20264 EDGAR
  13. Jun 18, 20268-K EDGAR
  14. Jun 12, 20264 EDGAR
  15. Jun 12, 20264 EDGAR
  16. Jun 12, 20264 EDGAR
  17. Jun 12, 20264 EDGAR
  18. Jun 12, 20264 EDGAR
  19. Jun 12, 20264 EDGAR
  20. Jun 11, 20268-K EDGAR

The 304 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 40 such filings since October 2021, the latest 10:

  1. Sep 17, 2026SCHEDULE 13G
  2. Aug 14, 2026SCHEDULE 13G/A
  3. Aug 14, 2026SCHEDULE 13G/A
  4. Aug 10, 2026SCHEDULE 13G
  5. May 15, 2026SCHEDULE 13G
  6. May 15, 2026SCHEDULE 13G/A
  7. May 15, 2026SCHEDULE 13G/A
  8. Feb 11, 2026SCHEDULE 13G/A
  9. Jan 29, 2026SCHEDULE 13G/A
  10. Nov 14, 2025SCHEDULE 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 6, 2026Raised $5 million in a private offering of equity Form D: 3 investors so far Form D
  2. Feb 5, 2024Raised $15 million in a private offering of equity Form D: 13 investors so far Form D
  3. Feb 17, 2023Filed a private offering of equity Form D: $10 million offered in all Form D
  4. Feb 3, 2023Raised $200,000 in a private offering of equity Form D: 1 investor so far Form D
  5. Oct 21, 2021Raised $67,258 in a private offering of equity Form D: 6 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Perceptive Advisors LLC438,471$1.2M0.0%New
ADAR1 Capital Management, LLC167,941$441.7K0.0%No change
Citadel Advisors LLC116,011$305.1K0.0%+66,478
Two Sigma Investments, LP88,792$233.5K0.0%New
Millennium Management LLC74,202$195.2K0.0%New
Renaissance Technologies LLC29,824$78.4K0.0%New
Geode Capital Management, LLC26,717$70.3K0.0%−21,133
Vanguard Capital Management LLC19,861$52.2K0.0%No change
Scientech Research LLC18,746$49.3K0.0%New
Vanguard Fiduciary Trust Co13,030$34.3K0.0%No change
LPL Financial LLC12,500$32.9K0.0%New
Dimensional Fund Advisors LP12,138$31.9K0.0%New
Northern Trust Corp11,767$30.9K0.0%New
Jane Street Group, LLC10,615$27.9K0.0%New
UBS Group AG1,961$5.2K0.0%+660
Caitong International Asset Management Co., Ltd1,813$4.8K0.0%+1,807
Morgan Stanley1,408$3.7K0.0%No change
Tower Research Capital LLC (TRC)837$2.2K0.0%−158
SBI Securities Co., Ltd.256$6730.0%No change
Hrt Financial LP58,612$1540.0%New
BlackRock, Inc.58$1530.0%No change
Activest Wealth Management2$50.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38